Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCT Oncternal Therapeutics, Inc. daily Stock Chart
ONCT [NASD]
Oncternal Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.65 Insider Own29.21% Shs Outstand15.42M Perf Week-5.39%
Market Cap62.30M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.89M Perf Month-4.04%
Income-35.40M PEG- EPS next Q- Inst Own8.70% Short Float0.85% Perf Quarter-27.08%
Sales1.70M P/S36.65 EPS this Y5.70% Inst Trans- Short Ratio4.23 Perf Half Y-21.40%
Book/sh1.18 P/B3.42 EPS next Y- ROA-129.00% Target Price1.50 Perf Year-39.55%
Cash/sh- P/C- EPS next 5Y0.00% ROE-161.10% 52W Range3.43 - 17.92 Perf YTD2.28%
Dividend- P/FCF- EPS past 5Y24.40% ROI- 52W High-77.46% Beta1.74
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low17.78% ATR0.26
Employees6 Current Ratio3.60 Sales Q/Q65.30% Oper. Margin- RSI (14)37.05 Volatility3.77% 5.39%
OptionableNo Debt/Eq0.00 EPS Q/Q88.40% Profit Margin- Rel Volume0.65 Prev Close4.12
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume21.99K Price4.04
Recom3.00 SMA20-3.70% SMA50-17.03% SMA200-30.27% Volume14,399 Change-1.94%
Dec-12-19 06:00PM  Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium Business Wire
Dec-11-19 08:00AM  Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma Business Wire -10.62%
Dec-09-19 08:00AM  Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting Business Wire
Dec-03-19 08:00AM  Oncternal Therapeutics to Present Cirmtuzumab Clinical Data Updates at 2019 ASH Annual Meeting and San Antonio Breast Cancer Symposium Business Wire
Nov-21-19 08:00AM  Oncternal Therapeutics to Present at Piper Jaffray Healthcare Conference Business Wire
Nov-14-19 04:02PM  Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting Business Wire
Nov-11-19 08:00AM  Oncternal Therapeutics to Present at Stifel Healthcare Conference Business Wire +5.74%
Nov-07-19 04:05PM  Oncternal Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-05-19 08:00AM  Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting Business Wire +8.80%
Oct-31-19 08:00AM  Oncternal Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update Business Wire
Oct-03-19 08:00AM  Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma Business Wire
Sep-20-19 12:03PM  We're Not Very Worried About Oncternal Therapeutics's (NASDAQ:ONCT) Cash Burn Rate Simply Wall St.
Sep-17-19 04:05PM  Oncternal Therapeutics Announces Presentation of Case Study of TK216 in Ewing Sarcoma Given at the Childrens Oncology Group Meeting Business Wire -5.70%
Sep-09-19 08:00AM  Oncternal Further Expands Executive Team; Appoints Gunnar Kaufmann, Ph.D., as Chief Scientific Officer and Igor Bilinsky, Ph.D., as Chief Business Officer Business Wire
Aug-28-19 04:01PM  Oncternal Expands Leadership Team with Appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior VP CMC and Manufacturing Business Wire
Aug-08-19 04:01PM  Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-06-19 08:00AM  Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib GlobeNewswire +5.75%
Aug-01-19 04:01PM  Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update GlobeNewswire -5.29%
Jun-10-19 08:00AM  Oncternal Therapeutics Completes Reverse Merger with GTx, Inc. GlobeNewswire -16.31%
Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.